Photo credit: Jacquelyn Martin

Where are the in­ter­change­able biosim­i­lars?

In June 2017, Leah Christl, for­mer biosim­i­lar lead at FDA, told a con­fer­ence in Chica­go that in­ter­change­able biosim­i­lars were like­ly com­ing to the US mar­ket with­in two years.

And al­though no in­ter­change­able biosim­i­lar has been ap­proved by FDA yet, and Christl has since moved on to Am­gen, progress on in­ter­change­able biosim­i­lars has been slow in the in­ter­ven­ing years.

Most re­cent­ly, Boehringer In­gel­heim an­nounced that it has com­plet­ed, as of last April, a switch­ing study nec­es­sary for launch­ing an in­ter­change­able biosim­i­lar for Hu­mi­ra (adal­i­mum­ab), al­though the com­pa­ny did not of­fer any fur­ther de­tails on the tim­ing of its sub­mis­sion to FDA or whether there will be an ad­vi­so­ry com­mit­tee to re­view the da­ta. Boehringer al­ready has an adal­i­mum­ab biosim­i­lar ap­proved by FDA, which it will launch in the US on 1 Ju­ly 2023.

In ad­di­tion, next March, in­sulin prod­ucts will make the tran­si­tion from be­ing reg­u­lat­ed un­der the FD&C Act to the PHS Act, which, ac­cord­ing to for­mer FDA Com­mis­sion­er Scott Got­tlieb means in­ter­change­able in­sulin prod­ucts are like­ly com­ing. FDA held a meet­ing in May on in­ter­change­able in­sulins, which will be par­tic­u­lar­ly im­por­tant as on­ly three fol­low-on in­sulin prod­ucts — Basaglar, Lus­duna and Ad­mel­og — have been ap­proved since 2015.

But out­side of the one po­ten­tial adal­i­mum­ab in­ter­change­able and sev­er­al pos­si­ble in­sulin in­ter­change­able prod­ucts (none of which have been pub­licly dis­closed), no oth­er com­pa­nies have even dis­closed be­gin­ning a switch­ing study. And al­though how such switch­ing stud­ies nec­es­sary for achiev­ing this des­ig­na­tion was on­ly fi­nal­ized last May, with FDA’s guid­ance on biosim­i­lar in­ter­change­abil­i­ty, com­pa­nies have known about the switch­ing study re­quire­ments since at least when the draft was re­leased in Jan­u­ary 2017.

Bern­stein an­a­lyst Ron­ny Gal told Fo­cus via email that Am­gen and San­doz have said they will pur­sue in­ter­change­able biosim­i­lars but switch­ing stud­ies have not list­ed yet.

Got­tlieb al­so said re­cent­ly in an in­ter­view that he be­lieves the use of switch­ing stud­ies to get an in­ter­change­abil­i­ty claim “is fair­ly ef­fi­cient, but I think there’s things that you can con­tin­ue to look at in terms of us­ing re­al-world ev­i­dence [RWE] and look­ing at how you struc­ture those switch­ing stud­ies to po­ten­tial­ly make it more ef­fi­cient.”

An­tho­ny Maf­fia, head of reg­u­la­to­ry af­fairs, North Amer­i­ca at San­doz, told Fo­cus in a phone in­ter­view that he agrees with Got­tlieb on the pos­si­ble use of RWE, “but the way it’s ap­plied needs flush­ing out.”

He al­so said he thinks the in­ter­change­abil­i­ty des­ig­na­tion is “cre­at­ing an ad­di­tion­al bar­ri­er to ac­cess, and we keep em­pha­siz­ing that and feel strong­ly that it’s unique to the US and sets us apart from oth­er glob­al health au­thor­i­ties.”

A lot of the dis­cus­sion on the sav­ings from biosim­i­lars is al­so cen­tered on the fact that state phar­ma­cy laws (45 states and Puer­to Ri­co have passed leg­is­la­tion, ac­cord­ing to Am­gen) stip­u­late that biosim­i­lars may on­ly be sub­sti­tut­ed at the phar­ma­cy if FDA has des­ig­nat­ed them as in­ter­change­able to their ref­er­ence prod­ucts.

“Un­less and un­til we change the way we pay for drugs more broad­ly, in­ter­change­ables are re­al­ly the cen­tral path to re­al com­pe­ti­tion and low­er prices,” Aaron Kessel­heim, di­rec­tor of the Pro­gram on Reg­u­la­tion, Ther­a­peu­tics and Law at Brigham and Women’s Hos­pi­tal, Har­vard Med­ical School, pre­vi­ous­ly ex­plained to Fo­cus.

But many bi­o­log­ics are ad­min­is­tered by physi­cians so the in­ter­change­abil­i­ty des­ig­na­tion will like­ly not be pur­sued in those in­stances. Oth­ers al­so have said in­ter­change­ables will not nec­es­sar­i­ly hit the mar­ket with as large of a dis­count as biosim­i­lars with­out the des­ig­na­tion.

In ad­di­tion, there is a lot of room for mis­in­for­ma­tion among phar­ma­cists and doc­tors. Hil­lel Co­hen, ex­ec­u­tive di­rec­tor of sci­en­tif­ic af­fairs at San­doz, pre­vi­ous­ly ex­plained how an in­ter­change­able biosim­i­lar is not more high­ly sim­i­lar than a non-in­ter­change­able biosim­i­lar, al­though the des­ig­na­tion may pro­vide the false per­cep­tion of a bet­ter prod­uct.

Maf­fia added that he thinks FDA “ab­solute­ly” must clar­i­fy when cer­tain com­pa­nies are spread­ing mis­in­for­ma­tion on biosim­i­lars. “We have to get to a com­mon set of lan­guage and that’s some­thing that FDA has a role in,” he said.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)

No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prognosis is poor for metastatic castration-resistant prostate cancer (mCRPC) patients. Novartis wants to change that by making its recently approved Pluvicto available to patients earlier in their course of treatment.

The Swiss pharma giant unveiled Phase III results Monday suggesting that Pluvicto was able to halt disease progression in certain prostate cancer patients when administered after androgen-receptor pathway inhibitor (ARPI) therapy, but without prior taxane-based chemotherapy. The drug is currently approved for patients after they’ve received both ARPI and chemo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

FDA grants or­phan drug des­ig­na­tion to Al­ger­non's ifen­prodil, while ex­clu­siv­i­ty re­mains un­clear

As the FDA remains silent on orphan drug exclusivity in the wake of a controversial court case, the agency continues to hand out new designations. The latest: Algernon Pharmaceuticals’ experimental lung disease drug ifenprodil.

The Vancouver-based company announced on Monday that ifenprodil received orphan designation in idiopathic pulmonary fibrosis (IPF), a chronic lung condition that results in scarring of the lungs.  Most IPF patients suffer with a dry cough, and breathing can become difficult.

Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er makes an­oth­er bil­lion-dol­lar in­vest­ment in Eu­rope and ex­pands again in Michi­gan

Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe.

The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over the past year. As a major piece of the manufacturing network for Covid-19 vaccines and antivirals, Pfizer is gearing up to place more money into the site. Pfizer announced it will place $750 million into the facility, mainly to establish “modular aseptic processing” (MAP) production and create around 300 jobs at the site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Yuling Li, Innoforce CEO

In­no­force opens new man­u­fac­tur­ing site in Chi­na

Innoforce is off to the races at its new site in the city of Hangzhou, China.

The Chinese CDMO announced last week that it has started manufacturing at the new facility, which was built to offer process development and manufacturing operations for RNA, plasmid DNA, viral vectors and other cell therapeutics. It will also serve as Innoforce’s corporate HQ.

The company said it’s investing more than $200 million in the 550,000-square-foot manufacturing base for advanced therapies. The GMP manufacturing facility features space for producing plasmids with three 30-liter bioreactors. For viral vector manufacturing, Innoforce also has 200- and 500-liter bioreactors at its disposal, along with eight suites to make cell therapies. The site also includes several labs and warehouse spaces.

Sekar Kathiresan, Verve Therapeutics CEO

Verve re­veals let­ter from FDA that lays out con­di­tions to lift base edit­ing tri­al hold

We now know why Verve’s lead candidate was placed on hold last month by US regulators.

In an SEC filing, Verve laid out the FDA’s conditions for lifting the hold on its lead therapy, VERVE-101. That includes submitting preclinical data about potency differences in human versus non-human cells, risks of gene editing germline cells, and off-target analyses in non-hepatocyte cell types.

The FDA also wants clinical data from the ongoing Heart-1 trial, and to modify the trial protocol in the US to add additional contraceptive measures and increase the length of a staggering interval between the dosing of participants.

Rick Modi, Affinia Therapeutics CEO

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Therapeutics has ditched its plans to go public in a relatively closed-door market that has not favored Nasdaq debuts for the drug development industry most of this year. A pandemic surge in 2020 and 2021 opened the doors for many preclinical startups, which caught Affinia’s attention and gave the gene therapy biotech confidence in the beginning days of 2022 to send in its S-1.

But on Friday, Affinia threw in the S-1 towel and concluded now is not the time to step onto Wall Street. The biotech has put out few public announcements since the spring of this year. Endpoints News picked the startup as one of its 11 biotechs to watch last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

TherapeuticsMD, a women’s health company whose one-time billion-dollar valuation seems a distant memory as its blockbuster aspirations petered out, is finally cashing out.

Australia’s Mayne Pharma is paying $140 million upfront to license essentially TherapeuticsMD’s whole portfolio, including two prescription drugs that treat conditions relating to menopause, a contraceptive vaginal ring as well as its prescription prenatal vitamin brands.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.